O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+2.19%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.03B
AUM Growth
+$5.03B
(-7.7%)
Cap. Flow
-$321M
Cap. Flow
% of AUM
-6.38%
Top 10 Holdings %
Top 10 Hldgs %
44.26%
Holding
122
New
8
Increased
22
Reduced
23
Closed
12
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$60.8M |
| 2 |
Integer Holdings
ITGR
|
$40.4M |
| 3 |
argenx
ARGX
|
$24.7M |
| 4 |
Exact Sciences
EXAS
|
$22.5M |
| 5 |
Amgen
AMGN
|
$22.3M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$106M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$103M |
| 3 |
Janux Therapeutics
JANX
|
$54.3M |
| 4 |
Esperion Therapeutics
ESPR
|
$36.7M |
| 5 |
Praxis Precision Medicines
PRAX
|
$28.1M |
Sector Composition
| 1 | Healthcare | 99.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Keros Therapeutics
KROS
$640M
| $58M | 1.14% |
1,268,734
| – | – |
|
27
Crinetics Pharmaceuticals
CRNX
$3.26B
| $57.4M | 1.13% |
1,280,800
-104,200
| -8% | -$4.67M |
|
28
UnitedHealth
UNH
$279B
| $57M | 1.13% |
112,000
+42,000
| +60% | +$21.4M |
|
29
ArriVent BioPharma
AVBP
$781M
| $56.2M | 1.11% |
3,027,328
| – | – |
|
30
Icon
ICLR
$14B
| $54.6M | 1.08% |
174,100
| – | – |
|
31
Terns Pharmaceuticals
TERN
$651M
| $51.9M | 1.02% |
7,619,135
| – | – |
|
32
Apellis Pharmaceuticals
APLS
$3.51B
| $50M | 0.99% |
1,302,800
+5,000
| +0.4% | +$192K |
|
33
Evolent Health
EVH
$1.11B
| $49.8M | 0.98% |
2,605,615
| – | – |
|
34
Xtant Medical Holdings
XTNT
$82.4M
| $46.1M | 0.91% |
73,114,592
| – | – |
|
35
Cytokinetics
CYTK
$5.98B
| $44M | 0.87% |
812,906
+130,206
| +19% | +$7.05M |
|
|
36
Amgen
AMGN
$153B
| $42.1M | 0.83% |
134,900
+71,500
| +113% | +$22.3M |
|
37
SI-BONE Inc
SIBN
$700M
| $41.8M | 0.82% |
3,229,977
+55,456
| +2% | +$717K |
|
38
Prelude Therapeutics
PRLD
$69.1M
| $41.6M | 0.82% |
10,909,256
| – | – |
|
|
VRNA
39
Verona Pharma
VRNA
$9.18B
| $41.4M | 0.82% |
2,861,801
-536,266
| -16% | -$7.75M |
|
40
Q32 Bio
QTTB
$20.9M
| $40.4M | 0.8% |
2,252,987
| – | – |
|
|
41
Integer Holdings
ITGR
$3.71B
| $40.4M | 0.8% |
+349,221
| New | +$40.4M |
|
42
Syndax Pharmaceuticals
SNDX
$1.39B
| $39.5M | 0.78% |
1,925,300
+176,300
| +10% | +$3.62M |
|
43
Geron
GERN
$893M
| $37.9M | 0.75% |
8,930,252
-3,963,359
| -31% | -$16.8M |
|
44
Xenon Pharmaceuticals
XENE
$2.99B
| $33.6M | 0.66% |
862,362
+312,362
| +57% | +$12.2M |
|
45
DexCom
DXCM
$30.9B
| $32.9M | 0.65% |
289,900
+149,600
| +107% | +$17M |
|
46
Rhythm Pharmaceuticals
RYTM
$6.75B
| $28.9M | 0.57% |
704,842
| – | – |
|
47
Avidity Biosciences
RNA
$6.12B
| $28.9M | 0.57% |
706,475
-287,625
| -29% | -$11.7M |
|
|
48
Exact Sciences
EXAS
$9.33B
| $28.4M | 0.56% |
672,416
+532,016
| +379% | +$22.5M |
|
49
Neuropace
NPCE
$310M
| $25.8M | 0.51% |
3,406,335
-597,632
| -15% | -$4.52M |
|
50
Dyne Therapeutics
DYN
$1.92B
| $25M | 0.49% |
708,400
| – | – |
|